WebRecently, a randomized phase III trial of lobe-specific versus systematic nodal dissection for clinical stage I–II NSCLC (JCOG1413) is being conducted, which has been enrolling patients since 2024 ; while the primary endpoint of the trial is the overall survival, the primary objective is to validate the non-inferiority of lobe-specific systematic nodal dissection … WebDISCLAIMER: The appearance of hyperlinks does not constitute endorsement by the 413th Flight Test Group, the U.S. Air Force Reserve, or the Department of Defense, of the …
肺がん外科グループ Lung Cancer Surgical Study Group:LCSSG
Web(新規審査) 研究課題番号:2024-362 研究責任者 山﨑 直也(中央病院) 研究課題名 jcog1605:パクリタキセル既治療原発性皮膚血管肉腫に対するパゾパニブ療法の非ラ … Webまた、適切なリンパ節郭清範囲の確立を目指し、jcog1413という臨床試験を行っています。 臨床病期I-II期の肺がんに対して、リンパ節郭清の範囲を縮小した選択的郭清法が、 … create a wim file
臨床病期I/II期非小細胞肺癌に対する選択的リンパ節郭清の治療的 …
Web5 nov 2024 · The clinical JCOG1413 trial, which was commenced in January 2024, will be the first phase III trial to confirm the superiority and the potential benefit of lobe-specific nodal dissection for clinical stage I–II NSCLC and it may support the selective lymphadenectomy as a potential standard approach for LN dissection in stage IA NSCLC . Web6 feb 2024 · A randomized Phase III trial of lobe-specific vs. systematic nodal dissection for clinical Stage I–II non-small cell lung cancer (JCOG1413) A randomized Phase III trial was commenced to confirm the clinical benefit of lobe-specific nodal dissection in comparison to systematic nodal dissection for clinical Stage I–II non-small cell lung cancer. WebJCOG1413 臨床病期I/II期非小細胞肺癌に対する選択的リンパ節郭清の治療的意義に関する ランダム化比較試験実施計画書ver. 1.3.0 A randomized phase III trial of lobe-specific … create a will and living trust